Number 5: Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of ...

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for ...

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to ...

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA ...